Latigo Biotherapeutics Inc.
NASDAQ:LTGOMedical - Pharmaceuticals
+$0.76 today
- Market cap
- $800.64M
- Beta
- 0.00
Volume 0.21M
Average 0.38M
LTGO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
EBITDA history
Currency unavailable · from the income statement
No EBITDA data reported for this period type.
EBITDA vs competitors
How LTGO compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $609.91M USD | +83.3% | +32.3% | 76.6% | |
| LTM Mar 2026 | $118.4M USD | +322.5% | -4.4% | 16.1% | |
| LTM Mar 2026 | -$374.35M USD | -462.2% | — | 1105.5% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding LTGO) | — | +83.3% | +13.9% | 76.6% | |
Competitors are the stored peer set for LTGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Latigo Biotherapeutics Inc.
NASDAQ:LTGO
Intrinsic Alpha fair value
Locked
Current Price
$13.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.